financetom
Market
financetom
/
Market
/
Goldman, Morgan Stanley CEOs warn of equity markets heading towards correction
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Goldman, Morgan Stanley CEOs warn of equity markets heading towards correction
Nov 4, 2025 3:19 AM

Nov 4 (Reuters) - Chief executives of Morgan Stanley ( MS )

and Goldman Sachs ( GS ) cautioned on Tuesday that the

global equity markets could be heading towards a correction,

underscoring a growing concern that investor optimism has

driven valuations to sky-high levels.

Fears of a market bubble come as the benchmark S&P 500

continues its meteoric climb, repeatedly hitting record

highs and evoking memories of the dot-com boom.

"We should welcome the possibility that there would be

drawdowns, 10% to 15%, that are not driven by some sort of macro

cliff effect," Morgan Stanley ( MS ) CEO Ted Pick said at the Global

Financial Leaders' Investment Summit in Hong Kong.

Markets have so far largely brushed aside concerns about

inflation, elevated interest rates, policy uncertainty from

shifting trade dynamics, and the ongoing federal government

shutdown, now in its fifth week.

"When you have these cycles, things can run for a period of

time. But there are things that will change sentiment and will

create drawdowns, or change the perspective on the growth

trajectory, and none of us are smart enough to see them until

they actually occur," Goldman CEO David Solomon said at the

summit.

Earlier this week, the co-chief investment officers of hedge

fund Bridgewater Associates had also warned that investors are

overlooking mounting risks to the current market stability and

the limits of the artificial intelligence boom, particularly in

the U.S.

(Reporting by Manya Saini and Niket Nishant in Bengaluru;

Editing by Arun Koyyur)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Spurred by Potential Tax-Cuts, Nvidia Earnings Momentum
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Spurred by Potential Tax-Cuts, Nvidia Earnings Momentum
Feb 26, 2025
08:18 AM EST, 02/26/2025 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust ( SPY ) was up 0.5% and the actively traded Invesco QQQ Trust (QQQ) advanced 0.7% in Wednesday's premarket activity amid renewed optimism over President Trump's tax-cut agenda and the upcoming Nvidia earnings report. US stock futures were also higher, with S&P 500...
Sector Update: Tech
Sector Update: Tech
Feb 26, 2025
08:47 AM EST, 02/26/2025 (MT Newswires) -- Technology stocks rose pre-bell Wednesday as the Technology Select Sector SPDR Fund (XLK) advanced by 1.1% and the SPDR S&P Semiconductor ETF (XSD) was up 2.4% recently. Super Micro Computer ( SMCI ) shares were over 19% higher after the company said it regained compliance with the Nasdaq's filing requirements. ...
US Equity Futures Rise Pre-Bell as Traders Await Nvidia Earnings
US Equity Futures Rise Pre-Bell as Traders Await Nvidia Earnings
Feb 26, 2025
08:18 AM EST, 02/26/2025 (MT Newswires) -- US equity futures were higher pre-bell Wednesday as traders awaited earnings results from artificial intelligence chip market bellweather Nvidia ( NVDA ) . The Dow Jones Industrial Average futures gained 0.2%, S&P 500 futures increased 0.4%, and Nasdaq futures were up 0.6%. Nvidia ( NVDA ) is scheduled to release its quarterly earnings...
Quantum Biopharma up in U.S. Pre-market, Says Phase 1 Lucid-MS Trial Completed With no Safety Concerns
Quantum Biopharma up in U.S. Pre-market, Says Phase 1 Lucid-MS Trial Completed With no Safety Concerns
Feb 26, 2025
08:53 AM EST, 02/26/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) rose 6.6% in U.S. pre-market trading on Wednesday after saying its Phase 1 trial investigating the safety and pharmacokinetics of its lead candidate Lucid-MS has been completed with no serious adverse events being reported. According to a statement, a final safety review committee meeting concluded that Lucid-MS was...
Copyright 2023-2026 - www.financetom.com All Rights Reserved